Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research.
Purity:
>95%
CAS Number:
[1062149-33-0]
Target:
TNF
* VAT and and shipping costs not included. Errors and price changes excepted
